Conflict of Interest in Pharma Commercial Services: A Manufacturer's Framework

Thesis

The operating thesis is that conflicts are rarely binary. A PBM-owned SP may be unavoidable for payer access, an integrated hub/SP may be efficient for a small launch, and a distributor-owned hub may simplify trade operations. The manufacturer risk is accepting bundled convenience without audit rights, data portability, independent routing criteria, and scenario language for PBM reform, 340B disputes, or copay-program changes.

Why This Matters

Every pharmaceutical manufacturer outsources critical commercialization functions — hub services, specialty pharmacy, copay assistance, data analytics — to third-party vendors. The consolidation of these vendors through PE roll-ups and vertical integration (PBMs owning specialty pharmacies, distributors owning hubs, hub vendors owning pharmacies) has created structural conflicts of interest that directly affect manufacturer economics, patient access, and data transparency.

This analysis provides a systematic framework for identifying, evaluating, and mitigating conflicts of interest when selecting and managing commercial services partners.

---

Framework: Five Categories of Conflict

1. PBM-Owned Specialty Pharmacy Self-Preferencing

The conflict: PBMs (CVS Caremark, Express Scripts, OptumRx) own specialty pharmacies and use formulary design, network narrowing, and benefit architecture to steer prescriptions to affiliated pharmacies — regardless of whether the affiliated pharmacy offers superior clinical outcomes or patient experience.

Evidence:

• FTC Second Interim Report (January 2025) documented that PBM-affiliated pharmacies generated $7.3 billion in revenue in excess of estimated drug acquisition costs from 2017-2022 on 51 specialty generic drugs (882 NDCs). Excess revenue grew at a 42% CAGR from 2017-2021. An additional $1.4 billion from spread pricing on the same drugs.
• Big Three PBMs controlled 44% of the commercial specialty generic 30-day market, yet 72% of drugs marked up >$1,000/Rx were dispensed by their affiliated pharmacies
• PBM-affiliated pharmacies were reimbursed at higher rates than unaffiliated pharmacies on nearly every specialty generic drug examined — some at 20-40x NADAC
• Big Three PBMs collectively captured 68% of U.S. specialty dispensing revenue in 2023 ($180B of $265B total), up from 54% in 2016
• CVS Caremark’s Specialty Connect routes fills through 9,000 CVS locations; exclusive network designs reject non-CVS pharmacy fills
• Express Scripts’ SaveOnSP copay maximizer requires routing through Accredo for specialty dispensing

Manufacturer impact:

• Reduced choice in specialty pharmacy selection for LDD programs
• Manufacturer hub programs become irrelevant when PBM mandates biosimilar substitution (Cordavis Hyrimoz replacing AbbVie’s Humira)
• Data transparency limited — PBM-owned pharmacies share less granular patient-level data with manufacturers than independent pharmacies
• Accumulator/maximizer programs redirect manufacturer copay dollars without corresponding patient benefit

Mitigation strategies:

• Design LDD networks with contractual minimum independent SP inclusion
• Negotiate data-sharing requirements in pharmacy contracts before launch
• Model accumulator/maximizer exposure in GTN forecasts with 30-50% impact assumption on affected plans
• Monitor state PBM divestiture legislation (Arkansas Act 624 was scheduled effective January 2026 but is currently enjoined by a July 2025 federal preliminary injunction; appellate ruling pending) that may force structural separation

2. Hub Vendor-Owned Specialty Pharmacy Channel Bias

The conflict: Hub vendors that own specialty pharmacies (EVERSANA, Cardinal Health/Sonexus; Cencora’s Lash Group hub was divested to CareMetx in Apr 2026, ending its distributor-owned vertical-capture status) have economic incentives to route patients to their affiliated pharmacy — even when an independent or PBM-owned pharmacy might be more appropriate for the patient’s benefit design.

Evidence:

• EVERSANA operates an owned specialty pharmacy as part of its integrated model, creating both end-to-end control and channel routing incentives
• Cencora retains specialty distribution + 3PL but divested its Lash Group hub to CareMetx in Apr 2026; CareMetx now operates the legacy hub footprint as a stand-alone platform without distributor ownership, removing this specific vertical-capture conflict from Cencora’s posture
• Cardinal Health/Sonexus integrates specialty distribution with hub enrollment and pharmacy fulfillment
• ConnectiveRx (independent, no owned pharmacy) positions this as a structural advantage: no channel bias

Manufacturer impact:

• Pharmacy routing recommendations may be driven by vendor economics rather than optimal patient access
• Manufacturers paying for hub services may inadvertently subsidize the vendor’s pharmacy business
• Difficult to audit whether pharmacy routing decisions are clinically vs. commercially motivated
• Bundled pricing (hub+pharmacy) can obscure the true cost of each service

Mitigation strategies:

• Require transparent pharmacy routing reports showing fill destinations and clinical rationale
• Include right-to-audit clauses in hub contracts covering pharmacy routing decisions
• Benchmark pharmacy routing against independent hub vendors (ConnectiveRx, AssistRx) as a control
• Consider separate hub and pharmacy vendor selection to eliminate structural conflict

3. Distributor-Owned Hub Services Vertical Capture

The conflict: The Big Three pharmaceutical distributors (McKesson, Cencora, Cardinal Health) have invested $16B+ in healthcare services acquisitions since 2011, creating vertically integrated platforms that combine wholesale distribution, hub services, specialty pharmacy, and data analytics. Manufacturers using these bundled services face concentration risk and reduced negotiating leverage.

Evidence:

• McKesson owns CoverMyMeds (electronic PA), RxCrossroads (hub services acquired from CVS in 2017), and specialty distribution
• Cencora owned Lash Group (largest distributor-owned hub) until Apr 2026, when it was divested to CareMetx; Cencora retains specialty distribution and specialty-pharmacy assets but no longer operates a hub directly
• Cardinal Health owns Sonexus (hub services), specialty pharmacy, and distribution
• Combined, the Big Three touch >90% of US pharmaceutical distribution

Manufacturer impact:

• Bundled commercial terms (“use our hub and get better distribution terms”) create implicit switching costs
• Data flows from hub enrollment, pharmacy dispensing, and distribution all consolidate within one entity — giving the distributor unmatched visibility into manufacturer commercial performance
• Manufacturers that split hub and distribution vendors may face less favorable distribution terms
• Concentration in three entities reduces manufacturer negotiating leverage

Mitigation strategies:

• Negotiate hub, pharmacy, and distribution contracts separately with explicit commercial terms for each
• Maintain relationships with independent hub vendors (ConnectiveRx, AssistRx, CareTria) as competitive alternatives
• Require data portability clauses that prevent lock-in if switching vendors
• Monitor the competitive dynamics between distributors — playing McKesson vs. Cencora vs. Cardinal maintains leverage

4. Data Ownership and Portability Disputes

The conflict: Hub vendors collect extensive patient-level data (enrollment, benefits, PA status, copay utilization, adherence) during program operation. When manufacturers want to switch hub vendors or analyze their own program data, they frequently discover that the data is treated as vendor property rather than manufacturer property.

Evidence:

• Hub contracts historically granted vendors broad rights to aggregated and de-identified data, even from manufacturer-specific programs
• Switching costs are amplified by data migration barriers — historical program data may not transfer cleanly to a new vendor
• Vendors use proprietary data formats and reporting platforms that create lock-in
• Manufacturer demand for data portability has increased significantly since 2023, creating vendor-manufacturer friction

Manufacturer impact:

• Inability to benchmark hub vendor performance without access to granular program data
• Switching costs elevated by data migration complexity
• Vendor-controlled analytics may present performance in the most favorable light
• Historical program data loss when changing vendors reduces institutional knowledge

Mitigation strategies:

• Negotiate explicit data ownership clauses at contract inception (not renewal) — manufacturer owns all patient-level program data
• Require data export in standard formats (CSV, FHIR, standard API) at any time during the contract
• Include transition assistance obligations specifying data transfer timelines and formats
• Require raw data access alongside vendor-curated dashboards to enable independent analysis

5. Copay Accumulator/Maximizer Programs as Systemic Conflict

The conflict: PBM copay accumulator and maximizer programs (CVS PrudentRx, Express Scripts SaveOnSP, OptumRx specialty accumulators) redirect manufacturer copay card dollars so they no longer count toward patient out-of-pocket maximums. This forces manufacturers to fund the full copay benefit without reducing patient cost obligations — systematically increasing manufacturer gross-to-net erosion while generating savings for the PBM/plan sponsor.

Evidence:

• As of 2025, 84% of commercially insured beneficiaries are in plans where accumulators are available; actual enrollment ~39%. Payers project growth to 48% accumulators and 57% maximizers by late 2025.
• DCI estimates plans and their vendors receive ~$6.5 billion of manufacturers’ copayment support funds annually
• Maximizer program vendors earn fees reported to be 25%+ of the value of a manufacturer’s copay support program
• Johnson & Johnson sued SaveOnSP in May 2022, alleging it paid $100 million more in copay assistance due to SaveOnSP’s practices
• FTC-ESI settlement (February 2026) requires Express Scripts to stop preferring high-list-price drug versions, provide net-cost-based member cost-sharing, and pass rebates directly to patients at POS beginning 2028. Expected to reduce patient costs by up to $7 billion over 10 years. Implementation deadline: January 1, 2027; decree effective for 10 years.
• 26 states (as of January 2026) have enacted anti-accumulator laws, affecting at least 16.8% of total US commercial market (~34.3 million individuals). Critical limitation: state laws only apply to fully insured plans, not self-funded ERISA plans.

Manufacturer impact:

• GTN erosion of 2-5% on affected brands, potentially higher for specialty drugs with high patient cost-sharing
• Hub copay enrollment workflows disrupted when PBM maximizer programs intercept the patient
• Manufacturer financial assistance budgets depleted faster without corresponding patient adherence benefit
• Creates perverse incentive for higher list prices to accommodate accumulator impact

Mitigation strategies:

• Model accumulator/maximizer exposure in all copay program budgets (assume 40-50% commercial plan exposure by 2027)
• Design copay programs with accumulator detection and dynamic benefit adjustment
• Engage market access and legal teams on state accumulator restriction legislation (varies by state)
• Evaluate alternative financial assistance models (PAPs, foundation programs) that bypass the accumulator mechanism

---

Decision Framework: When to Accept vs. Mitigate Conflict

Not all conflicts require elimination. Some vertically integrated vendors offer genuine operational efficiencies that outweigh the conflict risk. The decision framework:

Factor	Accept Conflict	Mitigate/Avoid Conflict
Program size	Small/mid programs ($2-8M) where operational simplicity matters	Large programs ($10M+) where economics justify separate vendor selection
Therapeutic area	Non-competitive classes where channel doesn’t affect market share	Competitive classes where pharmacy choice affects prescriber loyalty
Data sensitivity	Established brands with mature analytics	Launch products where early data shapes commercial strategy
Distribution model	Open distribution where pharmacy choice is patient-driven	LDD programs where pharmacy selection directly affects access
PBM exposure	Products with low commercial plan exposure	Products with high commercial plan exposure (accumulator risk)

---

Contract Clauses That Matter

Conflict analysis only becomes useful if it changes the contract. For manufacturer-side RFPs, the most important clauses are:

Clause	Conflict mitigated	Minimum standard
Pharmacy-routing transparency	Hub-owned SP, PBM-owned SP, distributor-owned channel bias	Monthly report of all recommended, routed, filled, rejected, and transferred prescriptions by destination and rationale
Data ownership and export	Vendor analytics lock-in	Manufacturer owns patient-level program data and can export raw data plus dashboards in a documented schema
Affiliate disclosure	Hidden economics across PBM, SP, distributor, GPO, or subcontractor	Vendor discloses all affiliates and subcontractors touching referral, dispensing, copay, data, or distribution workflows
Firewall / permitted-use language	PBM or channel affiliate monetizing manufacturer program data	Program data cannot be used for formulary, payer negotiation, competitive analytics, or affiliate commercialization without written consent
Unbundled pricing	Bundled service economics obscuring cross-subsidy	Hub, pharmacy, distribution, data, implementation, and analytics fees are separately priced even if purchased together
Transition assistance	Switching-cost leverage	Vendor supports successor transition, patient communications, data transfer, and open-case handoff under capped fees

These clauses do not eliminate all conflicts, but they convert vague concerns into audit rights, data rights, and operating evidence. A vendor unwilling to accept them is signaling that the conflict is not just theoretical.

---

Vendor Landscape: Conflict Profile by Vendor Type

Vendor Type	Example Vendors	Conflict Level	Primary Conflict
PBM-owned SP	CVS Specialty, Accredo, OptumRx SP	High	Self-preferencing, accumulator programs
Distributor-owned hub	McKesson/CoverMyMeds, Cardinal Health/Sonexus (Cencora exited via Lash Group divestiture to CareMetx Apr-2026)	Medium-High	Bundled commercial terms, data concentration
Hub with owned SP	EVERSANA	Medium	Pharmacy routing bias
Independent hub	ConnectiveRx, AssistRx, CareTria	Low	Data portability (standard vendor risk)
Tech-native hub	Phil, Neon Health, Claritas Rx	Low	Limited track record, scalability risk
Independent SP	PANTHERx, Orsini, BrightSpring	Low	PBM-independent = limited formulary access

---

Regulatory Landscape (2025-2026)

Regulation is moving in the direction of conflict reduction:

1. FTC PBM Investigation (2024-2026): Two interim reports documenting $7.3B in excess specialty generic revenue and $1.4B in spread pricing. FTC secured landmark ESI settlement (February 2026) requiring net-cost-based pricing, rebate pass-through by 2028, and 10-year compliance. Settlement talks with CVS Caremark and OptumRx ongoing.
2. Consolidated Appropriations Act of 2026 (CAA): Signed February 3, 2026. 100% rebate pass-through in Part D, PBMs classified as ERISA “covered service providers” with full compensation disclosure, mandatory semiannual reporting, independent audit rights. Effective for plan years beginning on or after August 3, 2028 (calendar-year plans: January 1, 2029).
3. Break Up Big Medicine Act (February 2026): Introduced by Senators Warren and Hawley. Would ban common ownership of insurer/PBM with provider/MSO, or provider/MSO with drug wholesaler. 1-year divestiture timeline. Status: introduced, not yet passed.
4. Arkansas PBM Divestiture Law (April 2025): First state to ban PBM pharmacy ownership (HB 1150/Act 624). Effective January 2026 but preliminary injunction issued July 2025 by federal judge on Commerce Clause grounds. Transition permits allowed through September 2027 for rare/orphan drugs.
5. State Accumulator/Maximizer Legislation: 26 states have enacted anti-accumulator laws as of January 2026. Colorado and California enacted PBM “delinking” laws prohibiting compensation tied to drug prices. All 50 states now have some form of PBM regulation.

---

Key Takeaways for Manufacturers

1. Map your conflict exposure before vendor selection. Use this framework to assess each potential vendor’s structural conflicts and determine whether operational efficiency justifies the risk.
2. Negotiate data ownership and portability at contract inception. Retaining these terms becomes progressively harder during renewals and after program launch.
3. Model accumulator/maximizer impact in all financial forecasts. The share of commercially insured lives in accumulator-eligible plans is growing annually. Assume worst-case exposure in GTN models.
4. Maintain competitive alternatives. The best mitigation for vendor conflict is credible alternatives. Maintain active relationships with independent vendors even if using integrated platforms.
5. Monitor regulatory developments. CAA 2026, state PBM divestiture laws, and FTC enforcement are reshaping the conflict landscape. Positioning ahead of regulatory changes creates commercial advantage.

Implications

Manufacturers should make conflict diligence a scored RFP workstream. For each vendor, require disclosure of owned pharmacies, PBM or payer ownership, distributor affiliations, copay/maximizer relationships, data resale rights, and subcontracted service layers. Then translate that disclosure into contract terms: routing audit rights, manufacturer-owned patient/program data, unbundled pricing, transition assistance, firewall commitments, and independent benchmark reporting.

The highest-risk areas are launch products, LDD products, and products with heavy commercial accumulator exposure. Those programs generate the most valuable early data and the most channel-routing leverage. For lower-risk or smaller programs, accepting an integrated vendor may be rational, but the contract should still preserve future optionality if regulation forces unbundling or if patient-level data becomes strategically important.

---

Related Pages

• Big Three PBM Specialty Pharmacy Operations
• PBM Ecosystem & Reform
• Copay Accumulators and Maximizers
• Drug Channel Economics
• Hub Services Market Analysis
• Gross-to-Net Dynamics